RecruitingNot Applicable

Taiwan Associated Genetic and Nongenetic Small Vessel Disease

Taiwan500 participantsStarted 2019-01-01

Plain-language summary

The TAG-SVD enrolled patients with clinical and neuroimaging features of cerebral small vessel disease (CSVD). All enrolled patients will receive next-generation sequence (NGS) with probes designed to target five candidate CSVD genes, and patients will be divided into genetic or non-genetic groups accordingly. Their clinical features and outcome will be followed for at least 2 years.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Participants must have at least one of the following symptoms/signs or history * stroke (especially small vessel occlusion type of ischaemic stroke, spontaneous ICH or young stroke) * cognitive impairment or dementia * gait disturbance * parkinsonism (especially vascular parkinsonism features) * headache (especially migraine) * positive family history of hereditary CSVD * MRI evidence of CSVD (MRI may be done for other reasons), including mild to moderate white matter hyper intensity, any lacune, or any cerebral microbleed Exclusion Criteria: * MRI evidence of CSVD due to other inflammatory, malignancy, or structural lesions * patients or family members not willing to sign informed consent

What they're measuring

Number of patients with incident stroke

Timeframe: 2 years

Trial details

NCT IDNCT05473637

SponsorNational Taiwan University Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12-31

Contact for this trial

Sung-Chun Tang, MD, PhD

886972651113 sctang@ntuh.gov.tw

View on ClinicalTrials.gov More Cerebral Small Vessel Diseases trials